Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL443790 | 0.97 | CA1 (0.34) | CA1CA2CA12CA7CA13 | |
| SCHEMBL461597 | 0.80 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL11821539 | 0.79 | CA1 (0.36) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6522462 | 0.75 | CA1 (0.35) | CA1CA2CA12CA7CA13 | |
| Benzene SCHEMBL29240836 | 0.75 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL859273 | 0.75 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL48385 | 0.74 | CA1 (0.38) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6512883 | 0.72 | CA1 (0.33) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6512888 | 0.72 | CA1 (0.33) | CA1CA2CA12CA7CA13 | |
| SCHEMBL6522388 | 0.72 | CA1 (0.33) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0719767-B1 | SUCCINAMIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | SENJU PHARMA CO (JP) | 2000-05-03 | — | — | EP | claimed |
| US-5688818-A | ENZYME INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | claimed |
| CN-1134699-A | Succinamic acid compound, process for producing the same, and use thereof | SENJU PHARMA CO (JP) | 1996-10-30 | — | — | CN | claimed |
| EP-0719767-A1 | SUCCINAMIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 1996-07-03 | — | — | EP | claimed |
| JP-7082259-A | — | — | None | — | — | JP | disclosed |
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7361671-B2 | Substituted heteroarylalkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-0719767-B1 | SUCCINAMIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | SENJU PHARMA CO (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0714893-B1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5700819-A | ALDOSE REDUCTASE ENZYME INHIBITOR | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5688818-A | ENZYME INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| CN-1134699-A | Succinamic acid compound, process for producing the same, and use thereof | SENJU PHARMA CO (JP) | 1996-10-30 | — | — | CN | disclosed |
| EP-0719767-A1 | SUCCINAMIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 1996-07-03 | — | — | EP | disclosed |
| EP-0714893-A1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
| JP-H0782259-A | SUCCINAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME FOR THERAPY OF DIABETIC COMPLICATIONS | SENJU PHARMACEUT CO LTD | 1995-03-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163535-A1 | Substituted Heteroarylalkanoic Acids | GPR119, LIPA, LIPC | CA1 3818/4885CA2 1778/4885CA12 2990/4885 |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | SLC5A2, GPR119, SLC5A1 | CA1 2400/4885CA2 815/4885CA12 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.